Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Spotlight Capital Holdings Inc (EM) SLCH

Spotlight Capital Holdings, Inc., through its subsidiaries, provides maintenance, repair, and overhaul products and services for aircraft in the general aviation sector in Florida. It offers various services that include federal aviation administration (FAA) certified repair station, major and minor airframe repairs, annual inspections, computerized aircraft weight and balance, aircraft modifications and STC kit installations, routine maintenance/insurance and accident repairs, composite airframe repairs, and pre-purchase inspections/log book analysis. The company also provides oxygen service/nitrogen service, service parts, janitrol/southwind heater service/AD compliance inspections, dye/fluorescent penetrant inspection service, aircraft exterior and interior detailing services, ACES dynamic propeller balancing service, avionics installations and repairs, minor paint repairs and detailing, instrument panel upgrades and component installs, engine scanners and monitor installation, a...


EXPM:SLCH - Post by User

Post by EllaMaeon Jun 03, 2022 5:04am
108 Views
Post# 34728738

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities